MicroRNAs in solid cancer
Read Online

MicroRNAs in solid cancer from biomarkers to therapeutic targets by OndЕ™ej SlabГЅ

  • 91 Want to read
  • ·
  • 7 Currently reading

Published by Nova Science in Hauppauge, N.Y .
Written in English


  • Biological Tumor Markers,
  • Cancer,
  • Physiopathology,
  • Neoplasms,
  • Gene therapy,
  • MicroRNAs,
  • Small interfering RNA,
  • Therapy,
  • Physiology,
  • Molecular Targeted Therapy

Book details:

Edition Notes

Includes bibliographical references and index.

Statementeditor, Ondrej Slaby
LC ClassificationsQP623.5.S63 M535 2012
The Physical Object
Paginationp. ;
ID Numbers
Open LibraryOL25263891M
ISBN 109781613245149
LC Control Number2011013685

Download MicroRNAs in solid cancer


This volume thoroughly explores of the functional role of microRNAs in cancer. It not only expertly describes the molecular mechanisms underlying the malignant transformation process but also compiles cutting-edge research on microRNAs in several forms of cancer, including colorectal cancer, pancreatic cancer, leukemia/lymphoma, prostate cancer, lung cancer, ovarian cancer, and bone cancer. Genre/Form: Electronic books: Additional Physical Format: Print version: MicroRNAs in solid cancer. Hauppauge, N.Y.: Nova Science, © (DLC)   DOI link for MicroRNAs in Cancer. MicroRNAs in Cancer book. MicroRNAs in Cancer. DOI link for MicroRNAs in Cancer. MicroRNAs in Cancer book. Edited By Cesar Lopez-Camarillo, Laurence A. Marchat. Edition 1st Edition. First Published eBook Published 22 February Pub. location Boca by: 4. The book “microRNAs in cancer” is an invaluable collection of the recent findings and reviews of leading experts about the current understanding of microRNAs roles in the development.

MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11(12)– PubMed Google Scholar Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH et al () Repression of the miR/ cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. MicroRNAs in Solid Tumors. Gianpiero Di Leva, Michela Garofalo Aberrant expression and function of microRNAs (miRNAs) in cancer have added a new layer of complexity to the understanding of development and progression of the disease state. This book devotes efforts to provide a broad framework for obtaining an in depth understanding of.   MicroRNAs have recently emerged as key regulators of gene expression during development and are frequently misexpressed in human disease states, in particular cancer. These nucleotide-long transcripts act to promote or repress cell proliferation, migration and apoptosis during development, all of which are processes that go awry in cancer. MicroRNAs (miRNAs) are evolutionarily conserved, naturally abundant, small, regulatory non-coding RNAs that inhibit gene expression at the post-transcriptional level in a sequence-specific manner. Each miRNA represses the protein expression of several coding genes in a manner proportional to the sequence complementarity with the target transcripts. MicroRNAs play key regulatory roles in.

MicroRNAs are short single-stranded RNAs that negatively regulate their target genes. In this chapter we will summarize our current knowledge of microRNA studies performed to better understand this dreadful disease. Many of these microRNAs regulate TGF-β directly, regulate genes in the TGF-β signaling pathway or vice versa creating networks.   The field of microRNA biology is really emerging in the last couple of years. Several investigators highlighted the importance of miRNAs in cancer. Although there is so much literature on microRNAs exist, a comprehensive book is still not available. Thus this book will be a great use to the scientists in the field of cancer biology. In addition, this book will be a good source of information.   1. Introduction. Prostate cancer (PCa) is the most commonly diagnosed solid cancer in men with an estimated incidence of 17, and mortality of in Australia, with an estimated incidence of , and mortality of 29, in the USA in (Siegel et al., ; AIHW, ).Following the introduction of prostate specific antigen (PSA) testing in blood for screening, the incidence of PCa. miR was found to be overexpressed in different types of solid cancers as well as lymphomas [20, –] miR is a negative prognostic factor in pancreatic and lung cancer patients [20, ]. In malignant glioma the downregulation of the GABA-A receptor was shown to .